Circular RNA VZV Immunogen Composition for Stable Vaccine Delivery

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for effective vaccines and therapeutics against varicella-zoster virus (VZV) to prevent and treat conditions such as chickenpox and shingles, as well as other neurologic complications associated with VZV infections.

Innovation Solution

Compositions of circular polyribonucleotides encoding VZV immunogens, including VZV glycoproteins like gE, gI, gB, gH, gK, gL, gC, gN, and gM, or their immunogenic fragments, are developed to induce an immune response and treat or prevent VZV-related diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If traditional vaccines are used to prevent VZV infections, then immunity is provided, but the vaccines require refrigeration and have complex administration requirements

Engineering Contradiction:

Improveimmunity effectivenessVSAvoidadministration convenience

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the physical state and stability parameters of the vaccine by using circular RNA instead of traditional viral vectors or inactivated viruses. This molecular structural change enables the vaccine to remain stable at room temperature, eliminating the need for refrigeration while maintaining immunogenicity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates a simplified copy of the viral antigens using circular RNA that encodes VZV glycoproteins, eliminating the need for complex viral cultivation and purification processes required by traditional vaccines, thereby simplifying manufacturing and administration

Inventive Principle:

Principle #26Copying

2Reliability

If live attenuated vaccines are used, then strong immune response is generated, but safety concerns arise from potential reversion to virulence

Engineering Contradiction:

Improveimmune response strengthVSAvoidsafety risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts only the essential immunogenic components (VZV glycoprotein coding sequences) from the complete viral genome and incorporates them into a circular RNA backbone. This extraction eliminates the viral replication machinery and pathogenic elements while retaining the ability to induce protective immunity

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The circular RNA acts as an intermediary that delivers viral antigen information to host cells without requiring actual viral infection. The circular RNA is translated by host ribosomes to produce viral glycoproteins that trigger immune responses, while the non-replicating nature of circular RNA prevents viral reversion risks

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250368688A1Varicella-zoster virus immunogen compositions and their uses

Publication Date: 2025.12.04 FLAGSHIP PIONEERING INNOVATIONS VI LLC

AI summary

This disclosure provides compositions, pharmaceutical preparations, and methods relating to circular polyribonucleotides encoding the expression of Varicella-Zoster Virus immunogens.